Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, announced that its scientific team will be presenting preclinical safety, pharmacokinetic and biomarker pharmacodynamic data at the American College of Chest Physicians’ annual CHEST 2019 meeting being held October 19 - 23 in New Orleans, Louisiana.
| CARY, N.C. and BASEL, Switzerland, Oct. 18, 2019 /PRNewswire/ -- Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, announced that its scientific team will be presenting preclinical safety, pharmacokinetic and biomarker pharmacodynamic data at the American College of Chest Physicians’ annual CHEST 2019 meeting being held October 19 - 23 in New Orleans, Louisiana. The CHEST poster, titled “Once Daily Oral Dosing of Rodatristat Ethyl (RVT-1201) Achieves Reductions in Serotonin Biosynthesis Comparable to those Associated with Reversal of Vascular Remodeling in PAH Animal Models,” will provide mechanistic preclinical pharmacodynamic and Phase 1 data that demonstrate administration of either once- or twice-daily rodatristat ethyl resulted in a similar reduction in serotonin biosynthesis, which was consistent with nonclinical efficacy. This abstract was selected by CHEST as a poster to be given as a short oral presentation, which will take place on October 22, 2019 at 1:00pm CDT in Poster Area 5 in the Exhibit Hall of Ernest N. Morial Convention Center. Rodatristat ethyl is a tryptophan hydroxylase (TPH) inhibitor designed to reduce the body’s peripheral production of serotonin. A significant body of scientific evidence supports dysregulated peripheral serotonin production as a trigger of aberrant proliferation and constriction of the smooth muscle cells in the wall of the pulmonary arteries, causing them to restrict blood flow in PAH. By lowering peripheral biosynthesis, it is believed that rodatristat ethyl may halt or reverse the pathology of diseases such as PAH, idiopathic pulmonary fibrosis (IPF) and sarcoidosis that are driven by aberrant serotonin signaling. Altavant is currently testing this mechanism of action in the ELEVATE 1 proof-of-concept Phase 2a study of rodatristat ethyl in patients with pulmonary arterial hypertension (PAH). About Pulmonary Arterial Hypertension About Altavant Sciences About Roivant Pharma About Roivant Sciences Contact:
SOURCE Altavant Sciences |
View original content:
